Traditionally, prognostic markers for breast cancer include histological grading, tumor-node-metastasis (TNM) staging, and molecular profiling, such as the expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This evidence concerns the gene ERBB2 and neoplasm.